Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis.

Caraffini V, Geiger O, Rosenberger A, Hatzl S, Perfler B, Berg JL, Lim C, Strobl H, Kashofer K, Schauer S, Beham-Schmid C, Hoefler G, Geissler K, Quehenberger F, Kolch W, Athineos D, Blyth K, Wölfler A, Sill H, Zebisch A.

Haematologica. 2019 May 16. pii: haematol.2018.209650. doi: 10.3324/haematol.2018.209650. [Epub ahead of print]

2.

Detection of AML-specific TP53 mutations in bone marrow-derived mesenchymal stromal cells cultured under hypoxia conditions.

Müller M, Graf R, Kashofer K, Macher S, Wölfler A, Zebisch A, Hrzenjak A, Heitzer E, Sill H.

Ann Hematol. 2019 Apr 2. doi: 10.1007/s00277-019-03680-4. [Epub ahead of print] No abstract available.

PMID:
30941510
3.

High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.

Daga S, Rosenberger A, Quehenberger F, Krisper N, Prietl B, Reinisch A, Zebisch A, Sill H, Wölfler A.

Cancer Med. 2019 Apr;8(4):1771-1778. doi: 10.1002/cam4.2053. Epub 2019 Mar 7.

4.

Imatinib stimulates prostaglandin E2 and attenuates cytokine release via EP4 receptor activation.

Bärnthaler T, Jandl K, Sill H, Uhl B, Schreiber Y, Grill M, Thomas D, Schicho R, Marsche G, Frank S, Heinemann A, Schuligoi R.

J Allergy Clin Immunol. 2019 Feb;143(2):794-797.e10. doi: 10.1016/j.jaci.2018.09.030. Epub 2018 Oct 16. No abstract available.

5.

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia.

Prochazka KT, Pregartner G, Rücker FG, Heitzer E, Pabst G, Wölfler A, Zebisch A, Berghold A, Döhner K, Sill H.

Haematologica. 2019 Mar;104(3):516-523. doi: 10.3324/haematol.2018.205013. Epub 2018 Oct 11.

6.

Expression profile of translation initiation factor eIF2B5 in diffuse large B-cell lymphoma and its correlation to clinical outcome.

Unterluggauer JJ, Prochazka K, Tomazic PV, Huber HJ, Seeboeck R, Fechter K, Steinbauer E, Gruber V, Feichtinger J, Pichler M, Weniger MA, Küppers R, Sill H, Schicho R, Neumeister P, Beham-Schmid C, Deutsch AJA, Haybaeck J.

Blood Cancer J. 2018 Aug 22;8(9):79. doi: 10.1038/s41408-018-0112-5. No abstract available.

7.

Feasibility and safety of using an automated decision support system for insulin therapy in the treatment of steroid-induced hyperglycemia in patients with acute graft-versus-host disease: A randomized trial.

Aberer F, Mader JK, Holzgruber J, Trummer C, Schwetz V, Pandis M, Pferschy PN, Greinix H, Tripolt NJ, Pieber TR, Zebisch A, Sill H, Wölfler A, Sourij H.

J Diabetes Investig. 2019 Mar;10(2):339-342. doi: 10.1111/jdi.12919. Epub 2018 Oct 1.

8.

Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.

Blatt K, Menzl I, Eisenwort G, Cerny-Reiterer S, Herrmann H, Herndlhofer S, Stefanzl G, Sadovnik I, Berger D, Keller A, Hauswirth A, Hoermann G, Willmann M, Rülicke T, Sill H, Sperr WR, Mannhalter C, Melo JV, Jäger U, Sexl V, Valent P.

Neoplasia. 2018 Jun;20(6):632-642. doi: 10.1016/j.neo.2018.04.004. Epub 2018 May 15.

9.

Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration.

Caraffini V, Perfler B, Berg JL, Uhl B, Schauer S, Kashofer K, Ghaffari-Tabrizi-Wizsy N, Strobl H, Wölfler A, Hoefler G, Sill H, Zebisch A.

Blood. 2018 Feb 15;131(7):826-830. doi: 10.1182/blood-2017-09-804906. Epub 2018 Jan 2. No abstract available.

10.

Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform.

Valent P, Stauder R, Theurl I, Geissler K, Sliwa T, Sperr WR, Bettelheim P, Sill H, Pfeilstöcker M.

Expert Rev Hematol. 2018 Feb;11(2):109-116. doi: 10.1080/17474086.2018.1420473. Epub 2018 Jan 2. Review.

PMID:
29292655
11.

Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.

Cooney JD, Lin AP, Jiang D, Wang L, Suhasini AN, Myers J, Qiu Z, Wölfler A, Sill H, Aguiar RCT.

Clin Cancer Res. 2018 Mar 1;24(5):1103-1113. doi: 10.1158/1078-0432.CCR-17-2218. Epub 2017 Dec 15.

12.

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.

Stefanzl G, Berger D, Cerny-Reiterer S, Blatt K, Eisenwort G, Sperr WR, Hoermann G, Lind K, Hauswirth AW, Bettelheim P, Sill H, Melo JV, Jäger U, Valent P.

Oncotarget. 2017 Jun 28;8(40):67709-67722. doi: 10.18632/oncotarget.18810. eCollection 2017 Sep 15.

13.

Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.

Gaksch L, Kashofer K, Heitzer E, Quehenberger F, Daga S, Hofer S, Halbwedl I, Graf R, Krisper N, Hoefler G, Zebisch A, Sill H, Wölfler A.

Am J Hematol. 2018 Jan;93(1):23-30. doi: 10.1002/ajh.24922. Epub 2017 Oct 19.

14.

Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.

Magina KN, Pregartner G, Zebisch A, Wölfler A, Neumeister P, Greinix HT, Berghold A, Sill H.

Blood. 2017 Aug 17;130(7):946-948. doi: 10.1182/blood-2017-04-777722. Epub 2017 Jul 5. Review. No abstract available.

15.

Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing.

Kashofer K, Gornicec M, Lind K, Caraffini V, Schauer S, Beham-Schmid C, Wölfler A, Hoefler G, Sill H, Zebisch A.

Leuk Lymphoma. 2018 Feb;59(2):501-504. doi: 10.1080/10428194.2017.1339879. Epub 2017 Jun 20. No abstract available.

16.

FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia.

Peschel I, Podmirseg SR, Taschler M, Duyster J, Götze KS, Sill H, Nachbaur D, Jäkel H, Hengst L.

Haematologica. 2017 Aug;102(8):1378-1389. doi: 10.3324/haematol.2016.160101. Epub 2017 May 18.

17.

IDH Mutation, Competitive Inhibition of FTO, and RNA Methylation.

Elkashef SM, Lin AP, Myers J, Sill H, Jiang D, Dahia PLM, Aguiar RCT.

Cancer Cell. 2017 May 8;31(5):619-620. doi: 10.1016/j.ccell.2017.04.001. No abstract available.

18.

The TP53 Pro72Arg SNP in de novo acute myeloid leukemia.

Schulz E, Sill H.

Haematologica. 2017 May;102(5):e214-e215. doi: 10.3324/haematol.2017.165019. No abstract available.

19.

Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease.

Stauber MN, Aberer F, Oulhaj A, Mader JK, Zebisch A, Pieber TR, Neumeister P, Greinix HT, Sill H, Sourij H, Wölfler A.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1186-1192. doi: 10.1016/j.bbmt.2017.03.010. Epub 2017 Mar 8.

20.

Hyperglycaemia within the first month after allogeneic haematopoietic stem-cell transplantation is an independent risk factor for overall survival in patients with acute myeloid leukaemia.

Aberer F, Kremser S, Mader JK, Zinke-Cerwenka W, Greinix H, Tripolt NJ, Pieber TR, Zebisch A, Sill H, Oulhaj A, Sourij H, Wölfler A.

Diabetes Metab. 2017 Dec;43(6):560-562. doi: 10.1016/j.diabet.2017.02.001. Epub 2017 Mar 6. No abstract available.

PMID:
28279650
21.

Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia.

Lal R, Lind K, Heitzer E, Ulz P, Aubell K, Kashofer K, Middeke JM, Thiede C, Schulz E, Rosenberger A, Hofer S, Feilhauer B, Rinner B, Svendova V, Schimek MG, Rücker FG, Hoefler G, Döhner K, Zebisch A, Wölfler A, Sill H.

Blood. 2017 May 4;129(18):2587-2591. doi: 10.1182/blood-2016-11-751008. Epub 2017 Mar 3. No abstract available.

22.

NR4A3 Suppresses Lymphomagenesis through Induction of Proapoptotic Genes.

Deutsch AJA, Rinner B, Pichler M, Prochazka K, Pansy K, Bischof M, Fechter K, Hatzl S, Feichtinger J, Wenzl K, Frisch MT, Stiegelbauer V, Prokesch A, Krogsdam A, Sill H, Thallinger GG, Greinix HT, Wang C, Beham-Schmid C, Neumeister P.

Cancer Res. 2017 May 1;77(9):2375-2386. doi: 10.1158/0008-5472.CAN-16-2320. Epub 2017 Mar 1.

23.

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.

Pleyer L, Döhner H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R.

Int J Mol Sci. 2017 Feb 15;18(2). pii: E415. doi: 10.3390/ijms18020415.

24.

Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host-disease.

Spindelboeck W, Schulz E, Uhl B, Kashofer K, Aigelsreiter A, Zinke-Cerwenka W, Mulabecirovic A, Kump PK, Halwachs B, Gorkiewicz G, Sill H, Greinix H, Högenauer C, Neumeister P.

Haematologica. 2017 May;102(5):e210-e213. doi: 10.3324/haematol.2016.154351. Epub 2017 Feb 2. No abstract available.

25.

The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia - results of two cohort studies involving 215 patients and 3759 controls.

Schulz E, Lind K, Renner W, Petersen BS, Quehenberger F, Dill C, Hofer S, Lal R, Hoefler G, Schlenke P, Ehninger G, Schetelig J, Middeke JM, Stölzel F, Sill H.

Br J Haematol. 2018 Apr;181(1):148-151. doi: 10.1111/bjh.14527. Epub 2017 Jan 20. No abstract available.

PMID:
28106906
26.

Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs.

Zebisch A, Hatzl S, Pichler M, Wölfler A, Sill H.

Int J Mol Sci. 2016 Dec 10;17(12). pii: E2080. Review.

27.

Evidence for a role of decitabine in the treatment of myeloid sarcoma.

Gornicec M, Wölfler A, Stanzel S, Sill H, Zebisch A.

Ann Hematol. 2017 Mar;96(3):505-506. doi: 10.1007/s00277-016-2870-0. Epub 2016 Nov 6. No abstract available.

PMID:
27817041
28.

Acute myeloid leukemia with TP53 germ line mutations.

Zebisch A, Lal R, Müller M, Lind K, Kashofer K, Girschikofsky M, Fuchs D, Wölfler A, Geigl JB, Sill H.

Blood. 2016 Nov 3;128(18):2270-2272. Epub 2016 Sep 12. No abstract available.

29.

Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.

Heidenreich S, Ziagkos D, de Wreede LC, van Biezen A, Finke J, Platzbecker U, Niederwieser D, Einsele H, Bethge W, Schleuning M, Beelen DW, Tischer J, Nagler A, Glass B, Maertens J, Yáñez L, Beguin Y, Sill H, Scheid C, Stelljes M, Ganser A, Zachée P, Selleslag D, de Witte T, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2017 Jan;23(1):44-52. doi: 10.1016/j.bbmt.2016.09.027. Epub 2016 Oct 5.

30.

Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP.

Hatzl S, Geiger O, Kuepper MK, Caraffini V, Seime T, Furlan T, Nussbaumer E, Wieser R, Pichler M, Scheideler M, Nowek K, Jongen-Lavrencic M, Quehenberger F, Wölfler A, Troppmair J, Sill H, Zebisch A.

Cancer Res. 2016 Jun 15;76(12):3644-54. doi: 10.1158/0008-5472.CAN-15-3049. Epub 2016 Apr 15.

31.

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.

Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl-Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Geissler D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R.

J Hematol Oncol. 2016 Apr 16;9:39. doi: 10.1186/s13045-016-0263-4.

32.

Pulmonary arterial pressure in patients with myelodysplastic syndromes.

Sill H, Kqiku-Kryeziu X, Avian A, Kovacs G, Gaal S, Zebisch A, Olschewski H.

Leuk Lymphoma. 2016 Nov;57(11):2723-6. doi: 10.3109/10428194.2016.1160086. Epub 2016 Apr 15. No abstract available.

PMID:
27082148
33.

Correspondence: Reply to 'SEMA4A variation and risk of colorectal cancer'.

Sill H, Schulz E, Steinke-Lange V, Boland CR.

Nat Commun. 2016 Mar 10;7:10695. doi: 10.1038/ncomms10695. No abstract available.

34.

Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.

Bainschab A, Quehenberger F, Greinix HT, Krause R, Wölfler A, Sill H, Zebisch A.

Leuk Res. 2016 Mar;42:47-51. doi: 10.1016/j.leukres.2016.01.014. Epub 2016 Feb 1.

PMID:
26866663
35.

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Sadovnik I, Hoelbl-Kovacic A, Herrmann H, Eisenwort G, Cerny-Reiterer S, Warsch W, Hoermann G, Greiner G, Blatt K, Peter B, Stefanzl G, Berger D, Bilban M, Herndlhofer S, Sill H, Sperr WR, Streubel B, Mannhalter C, Holyoake TL, Sexl V, Valent P.

Clin Cancer Res. 2016 Apr 15;22(8):2051-61. doi: 10.1158/1078-0432.CCR-15-0767. Epub 2015 Nov 25.

36.

Deletion of SPRY4 is a frequent event in secondary acute myeloid leukemia.

Geiger O, Hatzl S, Kashofer K, Hoefler G, Wölfler A, Sill H, Zebisch A.

Ann Hematol. 2015 Nov;94(11):1923-4. doi: 10.1007/s00277-015-2445-5. Epub 2015 Jul 25. No abstract available.

37.

D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2.

Lin AP, Abbas S, Kim SW, Ortega M, Bouamar H, Escobedo Y, Varadarajan P, Qin Y, Sudderth J, Schulz E, Deutsch A, Mohan S, Ulz P, Neumeister P, Rakheja D, Gao X, Hinck A, Weintraub ST, DeBerardinis RJ, Sill H, Dahia PL, Aguiar RC.

Nat Commun. 2015 Jul 16;6:7768. doi: 10.1038/ncomms8768.

38.

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia.

Cerny-Reiterer S, Rabenhorst A, Stefanzl G, Herndlhofer S, Hoermann G, Müllauer L, Baumgartner S, Beham-Schmid C, Sperr WR, Mannhalter C, Sill H, Linkesch W, Arock M, Hartmann K, Valent P.

Oncotarget. 2015 Feb 20;6(5):3071-84.

39.

Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.

Fisser MC, Rommer A, Steinleitner K, Heller G, Herbst F, Wiese M, Glimm H, Sill H, Wieser R.

Mol Carcinog. 2015 Dec;54(12):1815-9. doi: 10.1002/mc.22252. Epub 2014 Dec 9.

PMID:
25491945
40.

Identification of a novel variant of epsilon-gamma-delta-beta thalassemia highlights limitations of next generation sequencing.

Zebisch A, Schulz E, Grosso M, Lombardo B, Acierno G, Sill H, Iolascon A.

Am J Hematol. 2015 Mar;90(3):E52-4. doi: 10.1002/ajh.23913. Epub 2015 Jan 16. No abstract available.

41.

10th anniversary of the Austrian MDS Platform: aims and ongoing projects.

Burgstaller S, Bettelheim P, Krieger O, Machherndl-Spandl S, Nösslinger T, Pleyer L, Sill H, Sperr WR, Stauder R, Valent P, Pfeilstöcker M.

Wien Klin Wochenschr. 2015 Jan;127(1-2):12-5. doi: 10.1007/s00508-014-0627-0. Epub 2014 Nov 25.

PMID:
25421367
42.

Contaminated handwashing sinks as the source of a clonal outbreak of KPC-2-producing Klebsiella oxytoca on a hematology ward.

Leitner E, Zarfel G, Luxner J, Herzog K, Pekard-Amenitsch S, Hoenigl M, Valentin T, Feierl G, Grisold AJ, Högenauer C, Sill H, Krause R, Zollner-Schwetz I.

Antimicrob Agents Chemother. 2015 Jan;59(1):714-6. doi: 10.1128/AAC.04306-14. Epub 2014 Oct 27.

43.

A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies.

Ortega M, Bhatnagar H, Lin AP, Wang L, Aster JC, Sill H, Aguiar RC.

Leukemia. 2015 Apr;29(4):968-76. doi: 10.1038/leu.2014.302. Epub 2014 Oct 14.

44.

Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X.

Schulz E, Klampfl P, Holzapfel S, Janecke AR, Ulz P, Renner W, Kashofer K, Nojima S, Leitner A, Zebisch A, Wölfler A, Hofer S, Gerger A, Lax S, Beham-Schmid C, Steinke V, Heitzer E, Geigl JB, Windpassinger C, Hoefler G, Speicher MR, Boland CR, Kumanogoh A, Sill H.

Nat Commun. 2014 Oct 13;5:5191. doi: 10.1038/ncomms6191.

45.

Preexisting TP53 mutation in therapy-related acute myeloid leukemia.

Schulz E, Kashofer K, Heitzer E, Mhatre KN, Speicher MR, Hoefler G, Sill H.

Ann Hematol. 2015 Mar;94(3):527-9. doi: 10.1007/s00277-014-2191-0. Epub 2014 Aug 20. No abstract available.

46.

A gene expression profile associated with relapse of cytogenetically normal acute myeloid leukemia is enriched for leukemia stem cell genes.

Hackl H, Steinleitner K, Lind K, Hofer S, Tosic N, Pavlovic S, Suvajdzic N, Sill H, Wieser R.

Leuk Lymphoma. 2015 Apr;56(4):1126-8. doi: 10.3109/10428194.2014.944523. Epub 2014 Aug 18. No abstract available.

47.

Novel face of microRNA-155.

Neumeister P, Sill H.

Blood. 2014 Jan 2;123(1):5-7. doi: 10.1182/blood-2013-11-534107. No abstract available.

48.

Overexpression of primary microRNA 221/222 in acute myeloid leukemia.

Rommer A, Steinleitner K, Hackl H, Schneckenleithner C, Engelmann M, Scheideler M, Vlatkovic I, Kralovics R, Cerny-Reiterer S, Valent P, Sill H, Wieser R.

BMC Cancer. 2013 Jul 29;13:364. doi: 10.1186/1471-2407-13-364.

49.

Molecular cytogenetics and multiplex reverse-transcriptase polymerase chain reaction for risk stratification in acute myeloid leukemia.

Orendi K, Emberger W, Speicher MR, Hoefler G, Sill H.

J Clin Oncol. 2013 Jun 20;31(18):2360-1. doi: 10.1200/JCO.2013.48.8189. Epub 2013 May 6. No abstract available.

PMID:
23650414
50.

Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing.

Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldispuehl-Geigl J, Mauermann O, Lackner C, Höfler G, Eisner F, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR.

Cancer Res. 2013 May 15;73(10):2965-75. doi: 10.1158/0008-5472.CAN-12-4140. Epub 2013 Mar 7.

Supplemental Content

Support Center